• Idorsia flagged positive new post hoc analyses from its Phase 3 PRECISION study of aprocitentan in difficult-to-control hypertension.
• Results have not been presented yet; oral presentations are scheduled at AHA Hypertension 2026 in Arlington, Virginia, October 7-11.
• Data showed substantial blood-pressure lowering in patients with obesity-associated resistant hypertension, supporting endothelin pathway blockade as a treatment approach.
• A separate analysis reported strong efficacy across cardiovascular-kidney-metabolic stages, extending evidence for use across a broader cardiometabolic population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051145PRIMZONEFULLFEED1001276381) on October 05, 2026, and is solely responsible for the information contained therein.